| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199801270-00002 |
| P698 | PubMed publication ID | 9458007 |
| P2093 | author name string | Wang T | |
| Busuttil RW | |||
| Markowitz JS | |||
| Imagawa DK | |||
| Ke B | |||
| Spear GS | |||
| Goss JA | |||
| Seu P | |||
| Maggard MA | |||
| Swenson KM | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 155-160 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Fas ligand gene transfer to renal allografts in rats: effects on allograft survival | |
| P478 | volume | 65 |
| Q45879506 | A realistic chance for gene therapy in the near future |
| Q40874410 | Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system |
| Q36641367 | Adenoviral-mediated gene transfer in lymphocytes. |
| Q34214558 | Apoptosis and its clinical impact |
| Q35145645 | Biology of FasL. |
| Q47288500 | Blockade of Inflammation and Apoptosis Pathways by siRNA Prolongs Cold Preservation Time and Protects Donor Hearts in a Porcine Model |
| Q40793025 | Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells |
| Q40752695 | Exposure to exogenous DNA can modify the sensitivity of the Fas apoptotic pathway |
| Q47682583 | Fas Ligand gene transfer enhances the survival of tissue-engineered chondrocyte allografts in mini-pigs |
| Q36953140 | FasL expression on human nucleus pulposus cells contributes to the immune privilege of intervertebral disc by interacting with immunocytes. |
| Q40680142 | FasL-transfected endothelial cells decrease the proliferative response of allogeneic PBL. |
| Q34074844 | Gene therapy for kidney disease |
| Q35790872 | Gene therapy for renal disorders |
| Q34808035 | Gene therapy for renal disorders: what are the benefits for the elderly? |
| Q33734501 | Gene therapy in transplantation |
| Q83797705 | Gene therapy in transplantation |
| Q33840985 | Gene therapy in transplantation in the year 2000: moving towards clinical applications? |
| Q37786559 | Gene therapy to the kidney using viral vectors |
| Q45884035 | Gene transfer methods for transplantation |
| Q64379997 | Generation of FASL-expressing antigen-presenting cells for suppression of alloreactive T cells in the rat |
| Q59881175 | Immune privilege or inflammation? Insights into the Fas ligand enigma |
| Q41351550 | Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein |
| Q40944764 | Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis |
| Q77332256 | New approaches to inducing the death of alloreactive lymphocytes |
| Q38655427 | Novel technologies to engineer graft for tolerance induction |
| Q39640741 | Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice |
| Q42645944 | Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice |
| Q45883050 | Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning |
| Q37194997 | Proinflammatory consequences of transgenic fas ligand expression in the heart |
| Q35141421 | Renal gene transfer: nonviral approaches |
| Q34988364 | Stem cell medicine encounters the immune system |
| Q30479123 | TNF superfamily: a growing saga of kidney injury modulators. |
| Q40818613 | Target cells expressing CD95L are protected from lysis mediated by alloactivated T cells but are killed by resting NK cells |
| Q81094852 | The role of Fas ligand as an effector molecule in corneal graft rejection |
| Q34457197 | The role of Fas ligand in immune privilege |
| Q57704009 | Transplant tolerance: will genes protect the graft? |
Search more.